amantadine has been researched along with Psychoses in 18 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 9.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| " Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7." | 9.09 | Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001) |
| "Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])." | 5.16 | Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012) |
| " Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7." | 5.09 | Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001) |
| "Amantadine, which was originally developed as an antiviral medication, functions as a dopamine agonist in the central nervous system and consequently is utilized in the treatment of Parkinson disease, drug-induced extrapyramidal reactions, and neuroleptic malignant syndrome." | 3.85 | The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. ( Fox, J; Fryml, LD; Pelic, CG; Revuelta, GJ; Robert, S; Sahlem, G; Short, EB; Williams, KR, 2017) |
| "To investigate the association of illusions/hallucinations and plasma CRP levels in PD patients without symptomatic infections." | 1.40 | Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. ( Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K, 2014) |
| "Pergolide was increased to 8." | 1.33 | High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. ( Hundemer, HP; Oehlwein, C; Polzer, U; Schwarz, J; Storch, A; Trenkwalder, C; Winkelmann, J, 2005) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Tatar, D | 2 |
| Świerzy, K | 2 |
| Błachut, M | 2 |
| Badura Brzoza, K | 2 |
| Zaydlin, M | 1 |
| Bernal, JA | 1 |
| Bez, Y | 1 |
| Coffey, BJ | 1 |
| Fryml, LD | 1 |
| Williams, KR | 1 |
| Pelic, CG | 1 |
| Fox, J | 1 |
| Sahlem, G | 1 |
| Robert, S | 1 |
| Revuelta, GJ | 1 |
| Short, EB | 1 |
| Sawada, H | 1 |
| Oeda, T | 1 |
| Umemura, A | 1 |
| Tomita, S | 1 |
| Hayashi, R | 1 |
| Kohsaka, M | 1 |
| Yamamoto, K | 1 |
| Sudoh, S | 1 |
| Sugiyama, H | 1 |
| Hoffmann, VP | 1 |
| Case, M | 1 |
| Jacobson, JG | 1 |
| de Lucena, DF | 1 |
| Pinto, JP | 1 |
| Hallak, JE | 1 |
| Crippa, JA | 1 |
| Gama, CS | 1 |
| Bahk, WM | 1 |
| Lee, KU | 1 |
| Chae, JH | 1 |
| Pae, CU | 1 |
| Jun, T | 1 |
| Kim, KS | 1 |
| Storch, A | 1 |
| Trenkwalder, C | 1 |
| Oehlwein, C | 1 |
| Winkelmann, J | 1 |
| Polzer, U | 1 |
| Hundemer, HP | 1 |
| Schwarz, J | 1 |
| Visanji, NP | 1 |
| Gomez-Ramirez, J | 1 |
| Johnston, TH | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Brotchie, JM | 1 |
| Fox, SH | 1 |
| Danielczyk, W | 1 |
| Freudenreich, O | 1 |
| McEvoy, JP | 1 |
| Northoff, G | 1 |
| Lins, H | 1 |
| Böker, H | 1 |
| Danos, P | 1 |
| Bogerts, B | 1 |
| Floris, M | 1 |
| Lejeune, J | 1 |
| Deberdt, W | 1 |
| Eisdorfer, C | 1 |
| Dolezalová, B | 1 |
| Vacek, J | 1 |
| Sczesni, B | 1 |
| Becker, H | 1 |
| Schröder, J | 1 |
| Bittkau, S | 1 |
| von Baumgarten, F | 1 |
| Truong, DD | 1 |
| Przuntek, H | 1 |
| Castaigne, P | 1 |
| Laplane, D | 1 |
| Autret, A | 1 |
| Ferraris, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia[NCT00401973] | Phase 3 | 199 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | kilograms (Least Squares Mean) |
|---|---|
| Olanzapine | 2.76 |
| Olanzapine + Amantadine | 2.40 |
| Olanzapine + Metformin | 0.65 |
The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 48.24 | -13.89 |
| Olanzapine + Amantadine | 45.90 | -9.90 |
| Olanzapine + Metformin | 47.00 | -9.72 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 4.06 | -0.98 |
| Olanzapine + Amantadine | 4.03 | -0.72 |
| Olanzapine + Metformin | 4.00 | -0.79 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 12.76 | -6.39 |
| Olanzapine + Amantadine | 14.22 | -4.12 |
| Olanzapine + Metformin | 15.40 | -4.36 |
To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | correlation (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| EI: Disinhibition | EI: Cognitive Restraint | EI: Hunger | FCI: Carbohydrates/Starches (N=186, N=141) | FCI: Fast Food Fats (N=188, N=140) | FCI: High Fats (N=186, N=138) | FCI: Sweets (N=187, N=140) | FCI: Total Score (N=184, N=137) | |
| 2 Weeks | -0.034 | -0.273 | -0.150 | 0.013 | -0.019 | 0.051 | 0.022 | 0.039 |
| 22 Weeks | 0.285 | -0.038 | 0.148 | -0.064 | 0.047 | 0.043 | -0.008 | -0.000 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.32 | 0.26 |
| Olanzapine + Amantadine | 5.25 | 0.10 |
| Olanzapine + Metformin | 5.28 | 0.01 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.25 | -0.00 |
| Olanzapine + Amantadine | 1.26 | -0.11 |
| Olanzapine + Metformin | 1.22 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 3.02 | 0.16 |
| Olanzapine + Amantadine | 3.06 | -0.04 |
| Olanzapine + Metformin | 2.91 | -0.02 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimole per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.01 | 0.36 |
| Olanzapine + Amantadine | 5.03 | 0.01 |
| Olanzapine + Metformin | 4.91 | -0.08 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | millimoles per Liter (mmol/L) (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 1.58 | 0.33 |
| Olanzapine + Amantadine | 1.61 | 0.35 |
| Olanzapine + Metformin | 1.68 | 0.06 |
(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)
| Intervention | percent hemoglobin A1c (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Olanzapine | 5.51 | 0.09 |
| Olanzapine + Amantadine | 5.48 | 0.10 |
| Olanzapine + Metformin | 5.53 | -0.03 |
4 trials available for amantadine and Psychoses
| Article | Year |
|---|---|
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Pro | 2012 |
Open label study of the effect of amantadine on weight gain induced by olanzapine.
Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body We | 2004 |
Effect of amantadine on weight gain during olanzapine treatment.
Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Dopamine Agents; Female; Humans; Male; Ola | 2001 |
[Clinical study of the psychostimulant action of amantadine].
Topics: Amantadine; Antidepressive Agents; Attention; Central Nervous System; Clinical Trials as Topic; Coma | 1974 |
14 other studies available for amantadine and Psychoses
| Article | Year |
|---|---|
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.
Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2 | 2022 |
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.
Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2 | 2022 |
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.
Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2 | 2022 |
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.
Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2 | 2022 |
Improved Treatment Outcome with Haloperidol Decanoate and Amantadine in an Adolescent with Schizoaffective Disorder.
Topics: Adolescent; Amantadine; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Treatment Ou | 2023 |
The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.
Topics: Aged; Amantadine; Catatonia; Delirium; Dopamine Agents; Electroconvulsive Therapy; Humans; Male; Mid | 2017 |
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine A | 2014 |
Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder.
Topics: Adult; Amantadine; Catatonia; Female; Humans; Male; Psychotic Disorders; Receptors, N-Methyl-D-Aspar | 2012 |
High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combin | 2005 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
[Crises in the course of Parkinson's disease].
Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson | 1980 |
Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics.
Topics: Adult; Amantadine; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 1995 |
Therapeutic efficacy of N-methyl D-aspartate antagonist amantadine in febrile catatonia.
Topics: Adult; Amantadine; Bipolar Disorder; Catatonia; Dopamine Agents; Excitatory Amino Acid Agonists; Fev | 1999 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
[Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].
Topics: Amantadine; Humans; Levodopa; Mental Disorders; Parkinson Disease, Secondary; Psychotic Disorders | 1976 |
[Diagnostic and therapeutic aspects of neuroleptic malignant syndrome based on 12 cases].
Topics: Adult; Amantadine; Antipsychotic Agents; Bromocriptine; Dantrolene; Depressive Disorder; Diazepam; D | 1991 |
[Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa].
Topics: Affective Symptoms; Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Psychotic Disorde | 1971 |